Pericytes: a double-edged sword in cancer therapy.
暂无分享,去创建一个
Lei Deng | Nicholas G Zaorsky | Mao-Bin Meng | Huan-Huan Wang | Jiang Chao | Lu-Jun Zhao | Zhi-Yong Yuan | Wang Ping | L. Deng | Lujun Zhao | M. Meng | H. Wang | W. Ping | Z. Yuan | Jiang Chao
[1] Zainab N. Khan,et al. Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. , 2012, Cancer cell.
[2] D. Bodurka,et al. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers. , 2006, Gynecologic oncology.
[3] Jianhua Huang,et al. A Role for VEGF as a Negative Regulator of Pericyte Function and Vessel Maturation , 2008, Nature.
[4] Howard A. Fine,et al. Phase I/II Study of Imatinib Mesylate for Recurrent Malignant Gliomas: North American Brain Tumor Consortium Study 99-08 , 2006, Clinical Cancer Research.
[5] R. Jain. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] Y. Bang,et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. , 2011, The New England journal of medicine.
[7] Holger Gerhardt,et al. Pericytes limit tumor cell metastasis. , 2006, The Journal of clinical investigation.
[8] D. Hanahan,et al. Functions of Paracrine PDGF Signaling in the Proangiogenic Tumor Stroma Revealed by Pharmacological Targeting , 2008, PLoS medicine.
[9] D. Sargent,et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial , 2013, The Lancet.
[10] L. Ellis,et al. Overexpression of PDGF-BB decreases colorectal and pancreatic cancer growth by increasing tumor pericyte content. , 2007, The Journal of clinical investigation.
[11] 米永 吉邦. Absence of smooth muscle actin-positive pericyte coverage of tumor vessels correlates with hematogenous metastasis and prognosis of colorectal cancer patients , 2007 .
[12] O. Stoeltzing,et al. Targeting FGFR/PDGFR/VEGFR Impairs Tumor Growth, Angiogenesis, and Metastasis by Effects on Tumor Cells, Endothelial Cells, and Pericytes in Pancreatic Cancer , 2011, Molecular Cancer Therapeutics.
[13] H. Dvorak,et al. Heterogeneity of the Tumor Vasculature , 2010, Seminars in thrombosis and hemostasis.
[14] U. Gatzemeier,et al. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] B. Sennino. Two is better than one: Benefits of VEGF and PDGF inhibition in ovarian cancer , 2010, Cancer biology & therapy.
[16] J. Bergh,et al. Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer. , 2009, The American journal of pathology.
[17] D. Schadendorf,et al. Host-derived angiopoietin-2 affects early stages of tumor development and vessel maturation but is dispensable for later stages of tumor growth. , 2009, Cancer research.
[18] B. Teh,et al. Complexity of tumor vasculature in clear cell renal cell carcinoma , 2009, Cancer.
[19] Denis Lacombe,et al. Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] Hubing Shi,et al. Pulmonary vascular destabilization in the premetastatic phase facilitates lung metastasis. , 2009, Cancer research.
[21] R. Jain. A new target for tumor therapy. , 2009, The New England journal of medicine.
[22] P. Koumoutsakos,et al. Tumorigenesis and Neoplastic Progression Contrasting Actions of Selective Inhibitors of Angiopoietin-1 and Angiopoietin-2 on the Normalization of Tumor Blood Vessels , 2009 .
[23] R. Jain,et al. Angiopoietin-2 Interferes with Anti-VEGFR2–Induced Vessel Normalization and Survival Benefit in Mice Bearing Gliomas , 2010, Clinical Cancer Research.
[24] T. Sjöblom,et al. Tumors and an Associated Increase in Tumor Growth Rate Melanoma Cells Leads to Increased Pericyte Abundance in Platelet-Derived Growth Factor Production by B 16 Updated , 2004 .
[25] M. Skobe,et al. Platelet-derived growth factor-B normalizes micromorphology and vessel function in vascular endothelial growth factor-A-induced squamous cell carcinomas. , 2010, The American journal of pathology.
[26] Kristian Pietras,et al. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] W. Hong,et al. Phase II Trials of Imatinib Mesylate and Docetaxel in Patients with Metastatic Non-small Cell Lung Cancer and Head and Neck Squamous Cell Carcinoma , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[28] Xin Huang,et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial , 2006, The Lancet.
[29] P. Stattin,et al. Stromal PDGFRβ Expression in Prostate Tumors and Non-Malignant Prostate Tissue Predicts Prostate Cancer Survival , 2010, PloS one.
[30] C. Grommes,et al. Bevacizumab for the treatment of high-grade glioma: an update after Phase III trials , 2014, Expert opinion on biological therapy.
[31] K. Jennbacken,et al. Pericyte coverage decreases invasion of tumour cells into blood vessels in prostate cancer xenografts , 2009, Prostate Cancer and Prostatic Diseases.
[32] G. Bodoky,et al. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). , 2010, The oncologist.
[33] David J. Mooney,et al. Spatio–temporal VEGF and PDGF Delivery Patterns Blood Vessel Formation and Maturation , 2007, Pharmaceutical Research.
[34] G. Abou-Alfa,et al. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. , 2010, JAMA.
[35] M. Merchant,et al. Therapeutic angiogenesis due to balanced single‐vector delivery of VEGF and PDGF‐BB , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[36] C. Heldin,et al. Combined Anti-Angiogenic Therapy Targeting PDGF and VEGF Receptors Lowers the Interstitial Fluid Pressure in a Murine Experimental Carcinoma , 2009, PloS one.
[37] J. Leonard,et al. Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes. , 2013, Blood.
[38] Liz Y. Han,et al. Dual Targeting of Endothelial Cells and Pericytes in Antivascular Therapy for Ovarian Carcinoma , 2007, Clinical Cancer Research.
[39] C. Kuo,et al. Soluble receptor-mediated selective inhibition of VEGFR and PDGFRβ signaling during physiologic and tumor angiogenesis , 2008, Proceedings of the National Academy of Sciences.
[40] Shaun O'Brien,et al. Pericyte requirement for anti-leak action of angiopoietin-1 and vascular remodeling in sustained inflammation. , 2011, The American journal of pathology.
[41] Gabriele Bergers,et al. Modes of resistance to anti-angiogenic therapy , 2008, Nature Reviews Cancer.
[42] H. Augustin,et al. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. , 2000, Cancer research.
[43] K. Alitalo,et al. Vascular Endothelial Growth Factor-A and Platelet-Derived Growth Factor-B Combination Gene Therapy Prolongs Angiogenic Effects via Recruitment of Interstitial Mononuclear Cells and Paracrine Effects Rather Than Improved Pericyte Coverage of Angiogenic Vessels , 2008, Circulation research.
[44] D. McDonald,et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. , 2006, The Journal of clinical investigation.